阿司匹林一级预防获益机制新解

A analysis of benefits of aspirin therapy in cardiovascular primary prevention

众多临床试验证据表明,阿司匹林的应用是最有效的心血管病一级预防措施之一,其临床获益机制除抑制血小板聚集外,尚与抗炎、抗氧化和改善血管壁内皮细胞功能及抑制平滑肌细胞增殖有关。就阿司匹林抑制血小板聚集而言,于心血管病一级预防中其改善预后的机制是通过抑制血小板聚集介导的慢性炎症反应,而不是通过抑制血栓形成达成的。可见,阿司匹林一级预防的获益的关键与其干预动脉粥样硬化进程的机制密切相关。

Many previous data from clinical trials demonstrated that aspirin administration is one of the most effective thera- pies in cardiovascular primary prevention. Besides inhibiting platelet aggregation,aspirin is also of effects of anti-inflamma- tion, anti-oxidation and protection of endothelial function as well as inhibition of smooth muscle cell＇s proliferation. Consider- ing inhibiting platelet aggregation by aspirin as it stands, the mechanism for its clinical benefits is via the inhibition of plate- let aggregation which inducing chronic inflammation and atherosclerosis subsequently, but not inducing formation of thrombus. All in all,it is obvious and should be aware that the mechanism by which aspirin improves clinical outcome relies mainly on its action interfering with atherosclerotic pathogenesis and development in cardiovascular primary prevention.